UK-18892, a new aminoglycoside: an in vitro study.
UK-18892 is a new aminoglycoside antibiotic, a derivative of kanamycin A structurally related to amikacin. It was found to be active against a wide range of pathogenic bacteria, including many gentamicin-resistant strains. The spectrum and degree of activity of UK-18892 were similar to those of amikacin, and differences were relatively minor. UK-18892 was about twice as active as amikacin against gentamicin-susceptible strains of Pseudomonas aeruginosa. Both amikacin and UK-18892 were equally active against gentamicin-resistant strains of P. aeruginosa. There were no appreciable differences in the activity of UK-18892 and amikacin against Enterobacteriaceae and Staphylococcus aureus. Cross-resistance between these two antimicrobials was also apparent.
D000107:Acetylation; D000583:Amikacin / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism; D004755:Enterobacteriaceae / Q000187:drug effects; D005839:Gentamicins / Q000097:blood / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007612:Kanamycin / Q000031:analogs & derivatives*; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects
D001798:Blood Proteins; D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin; C016924:butikacin